Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review
AUTOR(ES)
Scarim, Cauê Benito, Ribeiro, Aline Rimoldi, Rosa, João Aristeu da, Chin, Chung Man
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2018-04
RESUMO
Abstract Chagas disease is a protozoan infection that was identified over a century ago. No drugs are available to treat the indeterminate and determinate chronic phases of the disease. Success of a drug design is dependent on correct biological evaluation. Concerning new drug designs for Chagas disease, it is essential to first identify the most effective, existing, experimental chronic protocols that can be used for comparison purposes. Here, we present a literature review regarding experimental models with chronic Chagas disease to evaluate the efficacy of benznidazole (BZN). We searched literature published in PubMed and Web of Science databases, using these keywords: animal model, BZN, Chagas disease, T. cruzi, and chronic phase, with no timeframe limitations. We excluded articles involving acute phase animal models and/or those without BZN treatment. The selected studies were conducted using different BZN concentrations (10mg-100mg) involving several different periods (5-70 days). Concentrations and durations of use are directly related to side effects, but do not prevent chronic tissue lesions. BZN use during the late/chronic phases of Chagas disease is unable to eliminate amastigote forms present in infected tissues. This study suggests the administration of a lower BZN concentration (<100mg/kg/day) during the chronic phase of the animal model, as this had been reported to result in fewer side effects.
Documentos Relacionados
- Chronic phase of Chagas disease: why should it be treated? A comprehensive review
- Paleoparasitology of Chagas disease: a review
- Back to the future in Chagas disease: from animal models to patient cohort studies, progress in immunopathogenesis research
- The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease
- Animal models of schizophrenia: a critical review